Phil McEwan
Chief Executive Officer, PhD
Paragraph style (light- 300) What sets us apart from other agencies is a combination of research and academic excellence, strategic awareness, and a dedication to providing innovative and novel solutions to research projects and deliverables.
Our experience and unique perspectives set us apart in navigating the complex interactions between healthcare payers, the pharmaceutical industry, patients and clinicians.
We pride ourselves on academic rigour, research excellence, and a flexible, client-focused model of business engagement.
HEOR Ltd is led by Professors Phil McEwan and Jason Gordon, who are supported by a team of experienced and dedicated medical writers, economists, statisticians, computer scientists, mathematicians and operational research analysts, and has access to extensive research expertise through its association with universities, other vendors and key opinion leaders.
Chronic hepatitis C virus (HCV) infection is associated with significant morbidity and mortality. The global prevalence of HCV infection has been estimated at 1.6% (1.3–2.1%), equivalent to 115 (92–149) million individuals. Whereas rates of infection are decreasing in the developed world, HCV related liver disease is expected to increase due to the latent nature of early infection and the significant number of undiagnosed cases.